This tumor acceleration was even more pronounced in the F1 cohorts, which showed a median survival of 235 days for invCAG-Luc and 140 days for invCAG-Mycl1-Luc (Fig 4D), highlighting the importance of Mycl1 in SCLC development. Here, MYCL is linked to neoplasm.